If the FDA's delay of approval for Corixa Corp.'s lead cancer product, Bexxar (tositumomab, iodine-131), is doing harm regarding investors, you wouldn't know it from the company's news Monday that it entered a purchase agreement to raise about $45 million in a private placement. (BioWorld Today)

A drug's blow-up in Phase III trials is hardly easy to take in stride, but Biogen Inc. came out of its failure last week seeming not much the worse for wear in the eyes of Wall Street, even if nobody at the company was popping champagne corks. (BioWorld Financial Watch)

With news that its deal with Aventis Pharmaceuticals Inc. to develop Picovir (pleconaril) is being terminated by mutual agreement, ViroPharma Inc.'s stock took another trouncing - and the company disclosed plans to restructure, cutting its work force by 63 percent. (BioWorld Today)

With the antibiotic dalbavancin in Phase II trials, Versicor Inc. said it has agreed to buy collaborator Biosearch Italia SpA - from which it gained the rights to the drug - for $260.7 million in a stock swap expected to close early next year. (BioWorld Today)

As promised, BioMarin Pharmaceutical Inc. put the finishing touches on its rolling biologics license application for Aldurazyme, the enzyme replacement therapy for mucopolysaccharidosis I. (BioWorld Today)